{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T13:27:33Z","timestamp":1780406853660,"version":"3.54.1"},"reference-count":104,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of the American Pharmacists Association"],"published-print":{"date-parts":[[2010,1]]},"DOI":"10.1331\/japha.2010.09124","type":"journal-article","created":{"date-parts":[[2010,1,27]],"date-time":"2010-01-27T02:08:02Z","timestamp":1264558082000},"page":"e1-e17","source":"Crossref","is-referenced-by-count":30,"title":["Pharmacogenomics: Bridging the gap between science and practice"],"prefix":"10.1016","volume":"50","author":[{"given":"Kelly C.","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph D.","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace M.","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1331\/JAPhA.2010.09124_bb0010","series-title":"Physicians' desk reference","author":"Thomson HealthCare","year":"2007"},{"key":"10.1331\/JAPhA.2010.09124_bb0015","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1001\/archinte.167.16.1752","article-title":"Serious adverse drug events reported to the Food and Drug Administration, 1998-2005","volume":"167","author":"Moore","year":"2007","journal-title":"Arch Intern Med"},{"key":"10.1331\/JAPhA.2010.09124_bb0020","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1056\/NEJMe0805136","article-title":"Pharmacogenomics and drug toxicity","volume":"359","author":"Nakamura","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1331\/JAPhA.2010.09124_bb0025","series-title":"Guidance for industry: E15 definitions for genomic biomarkers, pharmacogenomics, pharmacogenetics, genomic data and sample coding categories","author":"U.S. Food and Drug Administration","year":"2009"},{"key":"10.1331\/JAPhA.2010.09124_bb0030","series-title":"ICH topic E15: definitions for genomic biomarkers, pharmacogenomics, pharmacogenetics, genomic data and sample coding categories","author":"European Medicines Agency","year":"2009"},{"key":"10.1331\/JAPhA.2010.09124_bb0035","series-title":"Pharmacogenomics (PGx) Focus Group","author":"American Association of Pharmaceutical Scientists","year":"2009"},{"key":"10.1331\/JAPhA.2010.09124_bb0040","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1592\/phco.20.11.991.35270","article-title":"A vision of pharmacy's future roles, responsibilities, and manpower needs in the United States","volume":"20","author":"American College of Clinical Pharmacy","year":"2000","journal-title":"Pharmacotherapy"},{"key":"10.1331\/JAPhA.2010.09124_bb0045","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1126\/science.286.5439.487","article-title":"Pharmacogenomics: translating functional genomics into rational therapeutics","volume":"286","author":"Evans","year":"1999","journal-title":"Science"},{"key":"10.1331\/JAPhA.2010.09124_bb0050","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1001\/archinte.165.20.2331","article-title":"Implications of pharmacogenomics for drug development and clinical practice","volume":"165","author":"Ginsburg","year":"2005","journal-title":"Arch Intern Med"},{"key":"10.1331\/JAPhA.2010.09124_bb0055","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1592\/phco.28.8.992","article-title":"Pharmacogenomic biomarker information in drug labels approved by the United States Food and Drug Administration: prevalence of related drug use","volume":"28","author":"Frueh","year":"2008","journal-title":"Pharmacotherapy"},{"key":"10.1331\/JAPhA.2010.09124_bb0060","series-title":"Table of valid genomic biomarkers in the context of approved drug labels","author":"U.S. Food and Drug Administration","year":"2009"},{"key":"10.1331\/JAPhA.2010.09124_bb0065","first-page":"381","article-title":"Promises of biomarkers in drug development: a reality check. Chem Biol Drug Des","volume":"69","author":"Marrer","year":"2007","journal-title":"Jun"},{"key":"10.1331\/JAPhA.2010.09124_bb0070","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1517\/14622416.5.5.571","article-title":"From pharmacogenetics to personalized medicine: a vital need for educating health professionals and the community","volume":"5","author":"Frueh","year":"2004","journal-title":"Pharmacogenomics"},{"key":"10.1331\/JAPhA.2010.09124_bb0075","series-title":"A science primer","author":"National Center for Biotechnology Information","year":"2009"},{"key":"10.1331\/JAPhA.2010.09124_bb0080","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/441398a","article-title":"What is a gene?","volume":"441","author":"Pearson","year":"2006","journal-title":"Nature"},{"key":"10.1331\/JAPhA.2010.09124_bb0085","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1177\/0091270007303768","article-title":"A pharmacogenomics primer","volume":"47","author":"Court","year":"2007","journal-title":"J Clin Pharmacol"},{"key":"10.1331\/JAPhA.2010.09124_bb0090","series-title":"Goodman & Gilman's: the pharmacological basis of therapeutics","first-page":"93","article-title":"Pharmacogenetics","author":"Relling","year":"2006"},{"key":"10.1331\/JAPhA.2010.09124_bb0095","series-title":"Genetics home reference","author":"U.S. National Library of Medicine","year":"2009"},{"key":"10.1331\/JAPhA.2010.09124_bb0100","series-title":"Talking glossary of genetic terms","author":"National Human Genome Research Institute","year":"2009"},{"key":"10.1331\/JAPhA.2010.09124_bb0105","doi-asserted-by":"crossref","first-page":"231","DOI":"10.5414\/CPP41231","article-title":"Pharmacogenomics and drug response","volume":"41","author":"Muller","year":"2003","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1331\/JAPhA.2010.09124_bb0110","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1097\/00007691-199404000-00018","article-title":"Interethnic differences in omeprazole metabolism in the two S-mephenytoin hydroxylation phenotypes studies in Caucasian and Orientals","volume":"16","author":"Ishizaki","year":"1994","journal-title":"Ther Drug Monit"},{"key":"10.1331\/JAPhA.2010.09124_bb0115","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1097\/00008571-199512000-00004","article-title":"Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype","volume":"5","author":"Chang","year":"1995","journal-title":"Pharmacogenetics"},{"key":"10.1331\/JAPhA.2010.09124_bb0120","first-page":"694","article-title":"Thiopurine S-methyltransferase deficiency: two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians","volume":"58","author":"Tai","year":"1996","journal-title":"Am J Hum Genet"},{"key":"10.1331\/JAPhA.2010.09124_bb0125","first-page":"601","article-title":"Thiopurine pharmacogenetics: clinical and molecular studies of thiopurine methyltransferase","volume":"29","author":"Weinshilboum","year":"2001","journal-title":"Drug Metab Dispos"},{"key":"10.1331\/JAPhA.2010.09124_bb0130","doi-asserted-by":"crossref","first-page":"3473","DOI":"10.1073\/pnas.97.7.3473","article-title":"Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo","volume":"97","author":"Hoffmeyer","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1331\/JAPhA.2010.09124_bb0135","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1097\/01.fpc.0000178311.02878.83","article-title":"Multidrug resistance polypeptide (MDR1, ABCB1) variant 3435C>T affects mRNA stability","volume":"15","author":"Wang","year":"2005","journal-title":"Pharmacogenet Genomics"},{"key":"10.1331\/JAPhA.2010.09124_bb0140","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1086\/507101","article-title":"Drug transporter and metabolizing enzyme gene variants and nonnucleoside reverse-transcriptase inhibitor hepatotoxicity","volume":"43","author":"Ritchie","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1331\/JAPhA.2010.09124_bb0145","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1093\/clinchem\/47.6.1048","article-title":"No influence of the MDR-1 C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4-V allele) on dose-adjusted cyclosporin A trough concentrations or rejection incidence in stable renal transplant recipients","volume":"47","author":"von Ahsen","year":"2001","journal-title":"Clin Chem"},{"key":"10.1331\/JAPhA.2010.09124_bb0150","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/00008571-200302000-00005","article-title":"Genetic polymorphisms in MDR1 and CYP3A4 genes in Asians and the influence of MDR1 haplotypes on cyclosporin disposition in heart transplant recipients","volume":"13","author":"Chowbay","year":"2003","journal-title":"Pharmacogenetics"},{"key":"10.1331\/JAPhA.2010.09124_bb0155","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1111\/j.1600-051x.2004.00554.x","article-title":"P-glycoprotein drug transporter MDR1 gene polymorphism in renal transplant patients with and without gingival overgrowth","volume":"31","author":"Drozdzik","year":"2004","journal-title":"J Clin Periodontol"},{"key":"10.1331\/JAPhA.2010.09124_bb0160","first-page":"241","article-title":"MDR1 gene polymorphism in allogeenic kidney transplant patients with tremor","volume":"57","author":"Kotrych","year":"2005","journal-title":"Pharmacol Rep"},{"key":"10.1331\/JAPhA.2010.09124_bb0165","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1126\/science.1135308","article-title":"A \u201csilent\u201d polymorphism in the MDR1 gene changes substrate specificity","volume":"315","author":"Kimchi-Sarfaty","year":"2007","journal-title":"Science"},{"key":"10.1331\/JAPhA.2010.09124_bb0170","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1126\/science.1168750","article-title":"Structure of P-glycoprotein reveals a molecular basis of poly-specific drug binding","volume":"323","author":"Aller","year":"2009","journal-title":"Science"},{"key":"10.1331\/JAPhA.2010.09124_bb0175","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/S0026-895X(25)09788-3","article-title":"Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese","volume":"46","author":"DeMorais","year":"1994","journal-title":"Mol Pharmacol"},{"key":"10.1331\/JAPhA.2010.09124_bb0180","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S0009-9236(99)70075-5","article-title":"CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans","volume":"65","author":"Furuta","year":"1999","journal-title":"Clin Pharmacol Ther"},{"key":"10.1331\/JAPhA.2010.09124_bb0185","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.7326\/0003-4819-129-12-199812150-00006","article-title":"Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer","volume":"129","author":"Furuta","year":"1998","journal-title":"Ann Intern Med"},{"key":"10.1331\/JAPhA.2010.09124_bb0190","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1097\/00008571-199910000-00006","article-title":"Variability at the uridine diphosphate glucuronosyltransferase 1A1 promoter in human populations and primates","volume":"9","author":"Hall","year":"1999","journal-title":"Pharmacogenetics"},{"key":"10.1331\/JAPhA.2010.09124_bb0195","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1002\/cncr.21722","article-title":"Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy","volume":"106","author":"Massacesi","year":"2006","journal-title":"Cancer"},{"key":"10.1331\/JAPhA.2010.09124_bb0200","first-page":"943","article-title":"Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine\/sparteine polymorphism","volume":"48","author":"Gaedigk","year":"1991","journal-title":"Am J Hum Genet"},{"key":"10.1331\/JAPhA.2010.09124_bb0205","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S0022-3565(25)10669-1","article-title":"Ultrarapid hydroxylation of debrisoquine in a Swedish population: analysis of the molecular genetic basis","volume":"274","author":"Dahl","year":"1995","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1331\/JAPhA.2010.09124_bb0210","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1097\/GIM.0b013e31818de71c","article-title":"Abacavir hypersensitivity: a model system for pharmacogenetic test adoption","volume":"10","author":"Lai-Goldman","year":"2008","journal-title":"Genet Med"},{"key":"10.1331\/JAPhA.2010.09124_bb0215","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1097\/QAD.0b013e32830719aa","article-title":"First large, multicenter, open-label study utilizing HLA-B*5701 screening for abacavir hypersensitivity in North America","volume":"22","author":"Young","year":"2008","journal-title":"AIDS"},{"key":"10.1331\/JAPhA.2010.09124_bb0220","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.immuni.2008.04.020","article-title":"Human leukocyte antigen class I-restricted activation of CD8+ T cells provides the immunogenetic basis of a systemic drug hypersensitivity","volume":"28","author":"Chessman","year":"2008","journal-title":"Immunity"},{"key":"10.1331\/JAPhA.2010.09124_bb0225","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1056\/NEJMoa0706135","article-title":"HLA-B*5701 screening for hypersensitivity to abacavir","volume":"358","author":"Mallal","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1331\/JAPhA.2010.09124_bb0230","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1086\/529382","article-title":"High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients","volume":"46","author":"Saag","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1331\/JAPhA.2010.09124_bb0235","series-title":"Abacavir tablets: prescribing Information","author":"Ziagen","year":"2002"},{"key":"10.1331\/JAPhA.2010.09124_bb0240","series-title":"Guidelines for the use of antiretroviral agents in HIV-1 Infected adults and adolescents","author":"Office of AIDS Research Advisory Council","year":"2009"},{"key":"10.1331\/JAPhA.2010.09124_bb0245","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1097\/GIM.0b013e31815bf9a3","article-title":"Recommendations from the EGAPP Working Group: testing for cytochrome P450 polymorphisms in adults with nonpsychotic depression treated with selective serotonin reuptake inhibitors","volume":"9","author":"Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group","year":"2007","journal-title":"Genet Med"},{"key":"10.1331\/JAPhA.2010.09124_bb0250","doi-asserted-by":"crossref","first-page":"587","DOI":"10.2165\/00003088-200140080-00003","article-title":"Pharmacogenetics of warfarin elimination and its clinical implications","volume":"40","author":"Takahashi","year":"2001","journal-title":"Clin Pharmacokinet"},{"key":"10.1331\/JAPhA.2010.09124_bb0255","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/sj.tpj.6500285","article-title":"Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity","volume":"5","author":"Ingelman-Sundberg","year":"2005","journal-title":"Pharmacogenomics J"},{"issue":"146","key":"10.1331\/JAPhA.2010.09124_bb0260","first-page":"1","article-title":"Testing for cytochrome P450 polymorphisms in adults with non-psychotic depression treated with selective serotonin reuptake inhibitors (SSRIs)","volume":"Jan","author":"Matchar","year":"2007","journal-title":"Evid Rep Technol Assess (Full Rep)"},{"key":"10.1331\/JAPhA.2010.09124_bb0265","series-title":"Facts and comparisons 4.0","author":"Tamoxifen citrate","year":"2009"},{"key":"10.1331\/JAPhA.2010.09124_bb0270","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(05)66544-0","article-title":"Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials","volume":"365","year":"2005","journal-title":"Lancet"},{"key":"10.1331\/JAPhA.2010.09124_bb0275","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/sj.clpt.6100367","article-title":"Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response","volume":"83","author":"Goetz","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.1331\/JAPhA.2010.09124_bb0280","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1038\/sj.onc.1209377","article-title":"Cytochrome P450 pharmacogenetics and cancer","volume":"25","author":"Rodriguez-Antona","year":"2006","journal-title":"Oncogene"},{"key":"10.1331\/JAPhA.2010.09124_bb0285","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S0021-9258(19)70058-1","article-title":"Hydroxylated metabolites of tamoxifen are formed in vivo and bound to estrogen receptor in target tissues","volume":"256","author":"Borgna","year":"1981","journal-title":"J Biol Chem"},{"key":"10.1331\/JAPhA.2010.09124_bb0290","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0022-4731(82)90137-6","article-title":"Tamoxifen antiestrogens: a comparison of the activity, pharmacokinetics, and metabolic activation of the cis and trans isomers of tamoxifen","volume":"16","author":"Robertson","year":"1982","journal-title":"J Steroid Biochem"},{"key":"10.1331\/JAPhA.2010.09124_bb0295","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1023\/B:BREA.0000025406.31193.e8","article-title":"Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen","volume":"85","author":"Johnson","year":"2004","journal-title":"Breast Cancer Res Treat"},{"key":"10.1331\/JAPhA.2010.09124_bb0300","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1093\/jnci\/djg108","article-title":"Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine","volume":"95","author":"Stearns","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"10.1331\/JAPhA.2010.09124_bb0305","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1093\/jnci\/dji005","article-title":"CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment","volume":"97","author":"Jin","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"10.1331\/JAPhA.2010.09124_bb0310","doi-asserted-by":"crossref","first-page":"3708","DOI":"10.1200\/JCO.2006.06.8072","article-title":"Polymorphism in the CYP2D6 tamoxifen-metabolizing gene influences clinical effect but not hot flashes: data from the Italian Tamoxifen Trial","volume":"24","author":"Bonanni","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1331\/JAPhA.2010.09124_bb0315","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.clpt.2006.03.013","article-title":"Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment","volume":"80","author":"Borges","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"10.1331\/JAPhA.2010.09124_bb0320","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s10549-006-9428-0","article-title":"The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen","volume":"101","author":"Goetz","year":"2007","journal-title":"Breast Cancer Res Treat"},{"key":"10.1331\/JAPhA.2010.09124_bb0325","doi-asserted-by":"crossref","first-page":"5187","DOI":"10.1200\/JCO.2007.12.2705","article-title":"Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes","volume":"25","author":"Schroth","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1331\/JAPhA.2010.09124_bb0330","doi-asserted-by":"crossref","first-page":"9312","DOI":"10.1200\/JCO.2005.03.3266","article-title":"Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes","volume":"23","author":"Goetz","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1331\/JAPhA.2010.09124_bb0335","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s10549-004-7751-x","article-title":"Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients","volume":"91","author":"Nowell","year":"2005","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"10.1331\/JAPhA.2010.09124_bb0340","doi-asserted-by":"crossref","first-page":"R7","DOI":"10.1186\/bcr1640","article-title":"Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer","volume":"9","author":"Wegman","year":"2007","journal-title":"Breast Cancer Res"},{"key":"10.1331\/JAPhA.2010.09124_bb0345","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1001\/jama.2009.1420","article-title":"Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen","volume":"302","author":"Schroth","year":"2009","journal-title":"JAMA"},{"key":"10.1331\/JAPhA.2010.09124_bb0350","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s11239-007-0104-y","article-title":"Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues","volume":"25","author":"Gage","year":"2008","journal-title":"J Thromb Thrombolysis"},{"issue":"suppl 2","key":"10.1331\/JAPhA.2010.09124_bb0355","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1046\/j.1365-2362.33.s2.6.x","article-title":"Clinical relevance of genetic polymorphisms in the human CYP2C9 gene","volume":"33","author":"Schwarz","year":"2003","journal-title":"Eur J Clin Invest"},{"key":"10.1331\/JAPhA.2010.09124_bb0360","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/00008571-200204000-00010","article-title":"Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data","volume":"12","author":"Lee","year":"2002","journal-title":"Pharmacogenetics"},{"key":"10.1331\/JAPhA.2010.09124_bb0365","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1056\/NEJMoa044503","article-title":"Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose","volume":"352","author":"Rieder","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1331\/JAPhA.2010.09124_bb0370","doi-asserted-by":"crossref","first-page":"325","DOI":"10.2217\/17410541.2.4.325","article-title":"Pharmacogenomics steps toward personalized medicine","volume":"2","author":"Xie","year":"2005","journal-title":"Per Med"},{"key":"10.1331\/JAPhA.2010.09124_bb0375","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s10038-005-0354-5","article-title":"Association of VKORC1 and CYP2C9 polymorphisms with warfarin dose requirements in Japanese patients","volume":"51","author":"Mushiroda","year":"2006","journal-title":"J Hum Genet"},{"key":"10.1331\/JAPhA.2010.09124_bb0380","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1093\/hmg\/ddi180","article-title":"A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity","volume":"14","author":"Yuan","year":"2005","journal-title":"Hum Mol Genet"},{"key":"10.1331\/JAPhA.2010.09124_bb0385","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1097\/01.fpc.0000174789.77614.68","article-title":"Association of vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population","volume":"15","author":"Veenstra","year":"2005","journal-title":"Pharmacogenet Genomics"},{"key":"10.1331\/JAPhA.2010.09124_bb0390","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/j.1538-7836.2006.01759.x","article-title":"Population variation in VKORC1 haplotype structure","volume":"4","author":"Marsh","year":"2006","journal-title":"J Thromb Haemost"},{"key":"10.1331\/JAPhA.2010.09124_bb0395","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/GIM.0b013e31815bf924","article-title":"A rapid-ACCE review of CYP2C9 and VKORC1 alleles testing to inform warfarin dosing in adults at elevated risk for thrombotic events to avoid serious bleeding","volume":"10","author":"McClain","year":"2008","journal-title":"Genet Med"},{"key":"10.1331\/JAPhA.2010.09124_bb0400","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1001\/jama.287.13.1690","article-title":"Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy","volume":"287","author":"Higashi","year":"2002","journal-title":"JAMA"},{"key":"10.1331\/JAPhA.2010.09124_bb0405","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1055\/s-0037-1614114","article-title":"Genetic modulation of oral anticoagulation with warfarin","volume":"84","author":"Margaglione","year":"2000","journal-title":"Thromb Haemost"},{"key":"10.1331\/JAPhA.2010.09124_bb0410","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0140-6736(98)04474-2","article-title":"Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications","volume":"353","author":"Aithal","year":"1999","journal-title":"Lancet"},{"key":"10.1331\/JAPhA.2010.09124_bb0415","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1182\/blood.V96.5.1816","article-title":"Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment","volume":"96","author":"Taube","year":"2000","journal-title":"Blood"},{"key":"10.1331\/JAPhA.2010.09124_bb0420","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.clpt.2005.11.011","article-title":"Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements","volume":"79","author":"Aquilante","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"10.1331\/JAPhA.2010.09124_bb0425","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1056\/NEJMoa0809329","article-title":"Estimation of the warfarin dose with clinical and pharmacogenetic data","volume":"360","author":"Klein","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1331\/JAPhA.2010.09124_bb0430","doi-asserted-by":"crossref","first-page":"73","DOI":"10.7326\/0003-4819-150-2-200901200-00005","article-title":"Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation","volume":"150","author":"Eckman","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1331\/JAPhA.2010.09124_bb0435","author":"Coumadin prescribing information","year":"2009"},{"key":"10.1331\/JAPhA.2010.09124_bb0440","series-title":"Proposed decision memo for pharmacogenomic testing for warfarin response (CAG-00400N)","author":"Centers for Medicare & Medicaid Services","year":"2009"},{"key":"10.1331\/JAPhA.2010.09124_bb0445","series-title":"Decision memo for pharmacogenomic testing for warfarin response (CAG-00400N)","author":"Centers for Medicare & Medicaid Services","year":"2009"},{"key":"10.1331\/JAPhA.2010.09124_bb0450","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.2217\/14622416.8.11.1511","article-title":"Patients' and healthcare professionals' views on pharmacogenetic testing and its future delivery in the NHS","volume":"8","author":"Fargher","year":"2007","journal-title":"Pharmacogenomics"},{"key":"10.1331\/JAPhA.2010.09124_bb0455","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2217\/14622416.7.1.49","article-title":"Patients' and physicians' perspectives on pharmacogenetic testing","volume":"7","author":"Rogausch","year":"2006","journal-title":"Pharmacogenomics"},{"key":"10.1331\/JAPhA.2010.09124_bb0460","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1080\/03602530801952500","article-title":"A review of public policy issues in promoting the development and commercialization of pharmacogenomic applications: challenges and implications","volume":"40","author":"Garrison","year":"2008","journal-title":"Drug Metab Rev"},{"key":"10.1331\/JAPhA.2010.09124_bb0465","series-title":"Pharmacogenomics: applications to patient care","author":"American College of Clinical Pharmacy","year":"2004"},{"key":"10.1331\/JAPhA.2010.09124_bb0470","first-page":"843","article-title":"An ethical and legal overview of pharmacogenomics: perspectives and issues","volume":"27","author":"Sillon","year":"2008","journal-title":"Med Law"},{"key":"10.1331\/JAPhA.2010.09124_bb0475","series-title":"University of Michigan Center for Public Health and Community Genomics","year":"2009"},{"key":"10.1331\/JAPhA.2010.09124_bb0480","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1517\/phgs.4.3.231.22691","article-title":"An introduction to cost-effectiveness and cost-benefit analysis of pharmacogenomics","volume":"4","author":"Phillips","year":"2003","journal-title":"Pharmacogenomics"},{"key":"10.1331\/JAPhA.2010.09124_bb0485","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1001\/jama.286.18.2270","article-title":"Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review","volume":"286","author":"Phillips","year":"2001","journal-title":"JAMA"},{"key":"10.1331\/JAPhA.2010.09124_bb0490","doi-asserted-by":"crossref","first-page":"335","DOI":"10.2165\/00019053-200624040-00004","article-title":"Economic and developmental considerations for pharmacogenomic technology","volume":"24","author":"Vernon","year":"2006","journal-title":"Pharmacoeconomics"},{"key":"10.1331\/JAPhA.2010.09124_bb0495","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1097\/00008571-200406000-00002","article-title":"Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity","volume":"14","author":"Hughes","year":"2004","journal-title":"Pharmacogenetics"},{"key":"10.1331\/JAPhA.2010.09124_bb0500","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1097\/QAD.0b013e3283103ce6","article-title":"The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV","volume":"22","author":"Schackman","year":"2008","journal-title":"AIDS"},{"key":"10.1331\/JAPhA.2010.09124_bb0505","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/nrd1749","article-title":"Measuring the value of pharmacogenomics","volume":"4","author":"Phillips","year":"2005","journal-title":"Nat Rev Drug Discov"},{"key":"10.1331\/JAPhA.2010.09124_bb0510","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2165\/00019053-200422080-00001","article-title":"The role of cost-effectiveness analysis in the era of pharmacogenomics","volume":"22","author":"Flowers","year":"2004","journal-title":"Pharmacoeconomics"},{"key":"10.1331\/JAPhA.2010.09124_bb0515","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1159\/000189632","article-title":"Will pharmacogenomics disrupt the U.S. health care system? No","volume":"12","author":"Garrison","year":"2009","journal-title":"Public Health Genomics"},{"key":"10.1331\/JAPhA.2010.09124_bb0520","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1136\/bmj.308.6943.1552","article-title":"Diagnostic tests: sensitivity and specificity","volume":"308","author":"Altman","year":"1994","journal-title":"BMJ"},{"key":"10.1331\/JAPhA.2010.09124_bb0525","first-page":"597","article-title":"Understanding reliability and validity in qualitative research","volume":"8","author":"Golafshani","year":"2003","journal-title":"The Qualitative Report"}],"container-title":["Journal of the American Pharmacists Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S154431911530769X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S154431911530769X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T00:19:56Z","timestamp":1739751596000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S154431911530769X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1]]},"references-count":104,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,1]]}},"alternative-id":["S154431911530769X"],"URL":"https:\/\/doi.org\/10.1331\/japha.2010.09124","relation":{},"ISSN":["1544-3191"],"issn-type":[{"value":"1544-3191","type":"print"}],"subject":[],"published":{"date-parts":[[2010,1]]}}}